Article

More Quality Measures Needed for Cancer, Other Chronic Diseases

Author(s):

Among the 20 chronic conditions with the highest impact on the Medicare population, some have no quality measure, which limits Medicare's ability to pay for value.

For many chronic conditions, including many cancer types, there are not effective quality measurements in place, which limits Medicare's ability to pay for value, according to a new assessment from Avalere. Diabetes and chronic renal disease have 21 measures each, but prostate cancer and lung cancer only have 3 measure each.

Both endometrial cancer and Alzheimer's disease, which are among the conditions with the highest impact, currently have no Medicare quality measures, Avalere reported. These high-impact conditions are prioritized based on the relative cost, prevalence, variability, improvability, disease burden, and disparities of each chronic condition to the Medicare popultion.

“As Medicare and other payers move towards value-based payments for services and pharmaceuticals, we need more meaningful quality measures in oncology and selected other areas of medicine to ensure alignment," said Dan Mendelson, Avalere CEO.

Read more at Avalere: http://bit.ly/1fxTaxO

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Merrill H. Stewart, MD
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Hamlet Gasoyan, PhD
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo